2023 Ludvik B, Giorgino F, Jodar E et al (2021) Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial
This guide presents a comprehensive MOTS-c dosage chart and week-by-week titration protocol, grounded in the published literature, to help clinicians and educated patients understand both the rationale for dosing decisions and the practical parameters of a safe, evidence-informed approach
Overall, both serve to change the shape and look of the body, and more directly, its skin
We offer two types of GLP-1 medications, semaglutide and tirzepatide